General Information of Drug (ID: DMAQNBW)

Drug Name
AM103 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
56603665
TTD Drug ID
DMAQNBW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DG031 DMO3AJS Asthma CA23 Discontinued in Phase 3 [3]
GSK2190915 DM89AV2 Asthma CA23 Discontinued in Phase 2 [4]
GSK2190914 DMHZQ0T Asthma CA23 Discontinued in Phase 2 [5]
AZD4769 DMA3OWI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [6]
A-93178 DM1KBAY Allergy 4A80-4A85 Terminated [7]
L-671,480 DMP4QCJ Discovery agent N.A. Investigative [8]
L-689,037 DMCH3ZK Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Arachidonate 5-lipoxygenase activating protein (FLAP) TTDMBF5 AL5AP_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026047)
2 AM103 Experimental Treatment for Respiratory Diseases. Amira Pharmaceuticals/GSK. 2009.
3 BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72.
6 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72.
7 Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4.
8 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22-7.